NASDAQ · ZVRA
Zevra Therapeutics, Inc.
$10.25-$0.11 (-1.11%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.88% below the high.
Loading market information…
NASDAQ · YS · USD
Stock price, earnings
Quote as of May 24, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
YS Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow YS Biopharma Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
YS Biopharma Co., Ltd., a biopharmaceutical firm established in Beijing, China, in 2002, specializes in the discovery, development, production, and commercialization of vaccines and therapeutic biologics. Their primary focus is on addressing infectious diseases and cancer. Central to their efforts is a proprietary PIKA immunomodulating technology platform, which supports the creation of preventive and therapeutic biologics for conditions such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. The company extends its operations across multiple countries, including China, the United States, Singapore, the United Arab Emirates, and the Philippines.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.25-$0.11 (-1.11%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.88% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$4.07+$0.01 (+0.12%)
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
$7.12$0.00 (0.0%)
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$2.18+$0.02 (+0.93%)
Pardes Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
